A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease
A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft vs. host disease after allogenic stem cell transplantation
A Phase I Open-label Dose-escalation Study to Evaluate the Safety of Intramuscular Injections of PLX-R18 Cells in Subjects with Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
Phase 3 clinical trial of a novel oral benzimidazole riboside in transplant recipients with cytomegalovirus (CMV) infections that are refractory to available antiviral treatment
Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients Who Have Enrolled on BMT CTN 0702 BMT CTN 0702 Long-Term Follow-Up Version 1.0 dated September 30, 2014
Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation with Unrelated Donors
BMT CTN PROTOCOL 1302, Multicenter Phase II, Double Blind, Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma
Randomized study of autologous stem cell transplantation with high-dose melphalan versus high-dose melphalan and bortezomib in patients with MM 60 years or older